CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $587,866 | -24.1% | 32,623 | -32.4% | 0.27% | -57.4% |
| Q1 2023 | $774,815 | -54.9% | 48,245 | -48.6% | 0.63% | -38.1% |
| Q4 2022 | $1,718,242 | -5.0% | 93,893 | +2.0% | 1.02% | -1.3% |
| Q3 2022 | $1,808,000 | +194.5% | 92,047 | +179.4% | 1.03% | +178.4% |
| Q2 2022 | $614,000 | -36.8% | 32,948 | -25.5% | 0.37% | -39.9% |
| Q1 2022 | $971,000 | -35.5% | 44,226 | -16.5% | 0.62% | -48.5% |
| Q4 2021 | $1,505,000 | +211.6% | 52,982 | +71.8% | 1.20% | +240.3% |
| Q3 2020 | $483,000 | +7.3% | 30,845 | +20.0% | 0.35% | -5.6% |
| Q2 2020 | $450,000 | – | 25,701 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
| First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
| Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
| Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
| Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
| 5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
| MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
| Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
| Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |